As the biotechnology industry becomes more global, companies must evaluate and adopt various cross-border strategic models to drive capital formation and growth.
Reforms within China affecting the biomedical industry, such as the accelerated review and approval of drugs, and the expansion of the reimbursement scheme have provided a catalyst for transformation and innovation throughout Asia.
One year ago, the Hong Kong Exchange (HKEX) began to allow pre-revenue biotechnology companies to list – creating a new thriving IPO hub for innovative biopharmaceutical companies. HKEX is rapidly growing as a new financing channel for biotech companies and investors, with a recent wave of IPOs by Chinese biotech companies and more lining up.
Michael Chan, Senior Vice President of HKEX was instrumental in the decision to select biotech as the initial focus in widening market access for early stage companies. Following HKEX’s second annual Biotech Week this week in Hong Kong, Chan will be headed to the 2019 BIO International Convention in Philadelphia, PA to participate in BIO’s China Summit and Hong Kong Roundtable.
Chan will be participating in the panel listed below for a one-year look back on the takeaways from the HKEX listing rule, as well as discussions on investor strategies for the China market.
Emerging Opportunities in Global Markets:
China Summit Segment II: Cross-Border Outlook – Access to Capital and Partnering Strategies for the China Market
3:15 PM–4:15 PM Jun 3, 2019
113ABC: Level 100
Following that, on Tuesday, June 4, at the BIO International Convention, Chan will join a Roundtable Luncheon discussion of Hong Kong’s flourishing biotechnology industry and the development of the Greater Bay Area in China, which is conceived as the next Silicon Valley. Those interested in participating should RSVP to email@example.com by May 31, 2019.